Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world multicenter study of deutetrabenazine for tardive dyskinesia
ChiCTR2600132199Phase 4Not yet recruiting
- Sponsor
- Chaohu Hospital of Anhui Medical University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deutetrabenazine in tardive dyskinesia (TD), sponsored by Chaohu Hospital of Anhui Medical University. Primary endpoints: Abnormal Involuntary Movement Scale (AIMS) score change from baseline at Week 12 and Clinical response rate at Week 12. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
deutetrabenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on ChiCTR2600132199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132199.